The analyst maintains a BUY rating on NKE, citing they are "doing the right things" and he likes what he's seeing, despite lowering his price target due to a slower-than-expected turnaround. The prior strategy severely damaged wholesale relationships and product pipelines. The new management is rebuilding this support structure, which is leading to concrete improvements in sell-through rates and retailer relationships, particularly in North America. The operational "fracture" is healing, and the company is on the correct strategic path. The current low stock price presents a long-term opportunity as these corrective actions gradually restore health to the business. The recovery timeline remains uncertain and could be further delayed, especially in the critical China market. Continued execution missteps or a failure to reaccelerate growth would break the thesis.